Literature DB >> 20919962

Second AKT: the rise of SGK in cancer signalling.

Maressa A Bruhn1, Richard B Pearson, Ross D Hannan, Karen E Sheppard.   

Abstract

The serum and glucocorticoid kinase (SGK) family of serine/threonine kinases consists of three isoforms, SGK-1, SGK-2 and SGK-3. This family of kinases is highly homologous to the AKT kinase family, sharing similar upstream activators and downstream targets. SGKs have been implicated in the regulation of cell growth, proliferation, survival and migration: cellular processes that are dysregulated in cancer. Furthermore, SGKs lie downstream of phosphoinositide-3-kinase (PI3Kinase) signalling and interact at various levels with RAS/RAF/ERK signalling, two pathways that are involved in promoting tumorigenesis. Recent evidence suggests that mutant PI3Kinase can induce tumorigenesis through an AKT-independent but SGK3-dependent mechanism, thus implicating SGKs as potential players in malignant transformation. Here, we will review the current state of knowledge on the regulation of the SGKs and their role in normal cell physiology and transformation with a particular focus on SGK3.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20919962     DOI: 10.3109/08977194.2010.518616

Source DB:  PubMed          Journal:  Growth Factors        ISSN: 0897-7194            Impact factor:   2.511


  64 in total

1.  MiR-212-3p inhibits glioblastoma cell proliferation by targeting SGK3.

Authors:  Huailei Liu; Chenguang Li; Chen Shen; Fei Yin; Kaikai Wang; Yaohua Liu; Bingjie Zheng; Weiguang Zhang; Xu Hou; Xin Chen; Jianing Wu; Xiaoxiong Wang; Chen Zhong; Jiakang Zhang; Huaizhang Shi; Jing Ai; Shiguang Zhao
Journal:  J Neurooncol       Date:  2015-02-27       Impact factor: 4.130

2.  Functional Proteomics Identifies Acinus L as a Direct Insulin- and Amino Acid-Dependent Mammalian Target of Rapamycin Complex 1 (mTORC1) Substrate.

Authors:  Jennifer Jasmin Schwarz; Heike Wiese; Regine Charlotte Tölle; Mostafa Zarei; Jörn Dengjel; Bettina Warscheid; Kathrin Thedieck
Journal:  Mol Cell Proteomics       Date:  2015-04-23       Impact factor: 5.911

3.  Oncogenic Ras differentially regulates metabolism and anoikis in extracellular matrix-detached cells.

Authors:  J A Mason; C A Davison-Versagli; A K Leliaert; D J Pape; C McCallister; J Zuo; S M Durbin; C L Buchheit; S Zhang; Z T Schafer
Journal:  Cell Death Differ       Date:  2016-02-26       Impact factor: 15.828

4.  SGK3 (CISK) may induce tumor angiogenesis (Hypothesis).

Authors:  Minzhi Hou; Yingrong Lai; Shanyang He; Weiling He; Hongwei Shen; Zunfu Ke
Journal:  Oncol Lett       Date:  2015-05-06       Impact factor: 2.967

5.  Discovery of N-[4-(1H-Pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides as Highly Active and Selective SGK1 Inhibitors.

Authors:  Nis Halland; Friedemann Schmidt; Tilo Weiss; Joachim Saas; Ziyu Li; Jörg Czech; Matthias Dreyer; Armin Hofmeister; Katharina Mertsch; Uwe Dietz; Carsten Strübing; Marc Nazare
Journal:  ACS Med Chem Lett       Date:  2014-10-23       Impact factor: 4.345

6.  Autoimmunity: Rubbing salt in the wound.

Authors:  John J O'Shea; Russell G Jones
Journal:  Nature       Date:  2013-03-06       Impact factor: 49.962

7.  N-[4-(1H-Pyrazolo[3,4-B]pyrazin-6yl)-phenyl]-sulonamides and Their Use As Pharmaceuticals.

Authors:  Benjamin Blass
Journal:  ACS Med Chem Lett       Date:  2013-10-11       Impact factor: 4.345

8.  Identification, structure modification, and characterization of potential small-molecule SGK3 inhibitors with novel scaffolds.

Authors:  Grace Qun Gong; Ke Wang; Xin-Chuan Dai; Yan Zhou; Rajesh Basnet; Yi Chen; De-Hua Yang; Woo-Jeong Lee; Christina Maree Buchanan; Jack Urquhart Flanagan; Peter Robin Shepherd; Ying Chen; Ming-Wei Wang
Journal:  Acta Pharmacol Sin       Date:  2018-07-23       Impact factor: 6.150

9.  Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease.

Authors:  Steven Pennock; David Kim; Shizuo Mukai; Matthew Kuhnle; Dal W Chun; Joanne Matsubara; Jing Cui; Patrick Ma; David Maberley; Arif Samad; Robert J Van Geest; Sarit L Oberstein; Reinier O Schlingemann; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2013-04-09       Impact factor: 4.307

10.  Over-expression of LRIG1 suppresses biological function of pituitary adenoma via attenuation of PI3K/AKT and Ras/Raf/ERK pathways in vivo and in vitro.

Authors:  Shi-Qi Cheng; Heng-Yi Fan; Xin Xu; Wei-Wei Gao; Shi-Gang Lv; Min-Hua Ye; Miao-Jing Wu; Xiao-Li Shen; Zu-Jue Cheng; Xin-Gen Zhu; Yan Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.